Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Vyome Reports Sharp Reduction in Q3 2026 Loss Per Share; Advances Lead VT-1953 Program
Vyome Co-Founder Dr. Shiladitya Sengupta Promoted to Professor at Harvard Medical School
Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market
Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer
Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet
Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio
Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet
Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet
Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity
Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026
Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026
Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study
Vyome (NASDAQ:HIND) versus Medline (NASDAQ:MDLN) Critical Review
Vyome (NASDAQ:HIND) & Medline (NASDAQ:MDLN) Critical Analysis
Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company
Analyzing Profusa (NASDAQ:PFSA) & Vyome (NASDAQ:HIND)